NDAINTRAVENOUSSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
PEMFEXY (pemetrexed) by Eagle Pharmaceuticals is folate-dependent metabolic processes essential for cell replication. First approved in 2020.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEMFEXY (pemetrexed) is an intravenous antimetabolite that inhibits folate-dependent enzymes critical for DNA and RNA synthesis, blocking cell replication. It is a multi-targeted antifolate approved for oncology indications, particularly non-small cell lung cancer and mesothelioma. The drug works by inhibiting thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase after being transported into cells and converted to active polyglutamate forms.
Peak9.4 years to LOE
Product is at peak revenue stage with stable IV pricing; commercial team focus likely on market maintenance and payer negotiations.
Mechanism of Action
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
Started Jun 2027
16 enrolled
Lung Non-Squamous Non-Small Cell Carcinoma
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
Started Oct 2026
18 enrolled
Large B-cell LymphomaCentral Nervous System Lymphoma
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
Started Aug 2026
430 enrolled
NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Started Nov 2025
500 enrolled
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Started Oct 2025
600 enrolled
Non-Small Cell Lung CancerKRAS G12C Lung Cancer
Worked on PEMFEXY at Eagle Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.